ImmunityBio Stock Rises on FDA Acceptance of Supplemental BLA for Anktiva
Shares of ImmunityBio (NASDAQ: IBRX) rose 9% after the company announced that its supplemental biologics license application for Anktiva was accepted by the FDA. The approval could expand the drug's label to include treatment for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with papillary disease, significantly broadening its market potential.
Tickers: $IBRX
Topics: Anktiva FDA Non-Muscle Invasive Bladder Cancer (NMIBC) stock movement